BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 38686714)

  • 1. PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site.
    Junior JNA; Preto DD'; Lazarini MEZN; de Lima MA; Bonatelli M; Berardinelli GN; da Silva VD; Pinheiro C; Reis RM; Cárcano FM
    Int J Clin Oncol; 2024 Jun; 29(6):726-734. PubMed ID: 38528294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
    Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
    J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 mRNA and protein expression in canine mammary carcinomas: Correlation with histopathological grade and molecular markers.
    Bae MK; Ko YU; Seung BJ; Sur JH; Choe NH
    Vet Pathol; 2024 May; 61(3):402-409. PubMed ID: 38281145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic impact of programmed death - 1 in the treatment of colorectal cancer.
    Sangani PS; Yazdani S; Khalili-Tanha G; Ghorbani E; Al-Hayawi IS; Fiuji H; Khazaei M; Hassanian SM; Kiani M; Ghayour-Mobarhan M; Ferns GA; Nazari E; Avan A
    Pathol Res Pract; 2024 May; 259():155345. PubMed ID: 38805760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation.
    Srivastava P; Husain N; Shukla S; Chauhan S; Pandey A; Masood S
    Indian J Pathol Microbiol; 2021; 64(3):490-496. PubMed ID: 34341259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathological Types,Expression of Mismatch Repair Protein,Human Epidermal Growth Factor Receptor 2,and Pan-TRK,and Eostein-Barr Virus Infection in Patients With Colorectal Cancer Resected in Tibet].
    Luo HH; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Guo PP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):422-428. PubMed ID: 37407529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
    Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.